Drug Profile
AEOL 10150
Alternative Names: AEOL-10150; MnTDEIPLatest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Duke University; National Jewish Medical and Research Center
- Developer Aeolus Pharmaceuticals Inc; National Institutes of Health (USA); National Jewish Medical and Research Center; United States Army Medical Research Institute of Chemical Defense; University of Colorado at Denver
- Class Oxidoreductases; Porphyrins; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Antioxidants; Free radical scavengers; Oxygen radical scavengers; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute lung injury; Acute radiation syndrome; Amyotrophic lateral sclerosis; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetes mellitus; Gastrointestinal disorders; Idiopathic pulmonary fibrosis; Lung disorders; Mucositis; Poisoning; Radiation injuries; Skin disorders; Solid tumours; Spinal cord injuries; Stroke
Most Recent Events
- 10 Mar 2023 Discontinued - Phase-I for Amyotrophic lateral sclerosis in USA (SC), before March 2023 (NDR batch 29)
- 10 Feb 2023 Discontinued - Phase-I for Acute radiation syndrome (In volunteers) in USA (SC)
- 10 Feb 2023 Discontinued - Preclinical for Acute lung injury in USA (SC)